Sermorelin: The Most Clinically Validated GH-Stimulating Peptide

Sermorelin is the rare peptide that actually cleared FDA approval. It was a marketed drug, withdrawn in 2008 for business reasons, not safety. Here’s the part that gets skipped: it was studied and approved in people with a GH deficiency, and the people buying it now mostly don’t have one. That gap is the story, so let’s start there.

What sermorelin is

Sermorelin is a synthetic 29-amino-acid peptide. It’s the first 29 residues of your own growth hormone-releasing hormone (GHRH 1-29), the hypothalamic signal that tells the pituitary to release GH. Native GHRH is 44 amino acids; sermorelin is the active business end, the part that binds and switches on the GHRH receptor on pituitary somatotroph cells.

Unlike fully synthetic secretagogues like ipamorelin or CJC-1295, sermorelin mimics the body’s own GHRH signal directly instead of going through the ghrelin receptor. That keeps the normal pulsing pattern of GH release rather than forcing it above natural peaks. The developers treated that as a safety feature, because they were wary of what straight exogenous GH does.

The clinical record — and who it was studied in

Sermorelin has a deeper published clinical record than anything else in this overview, because it was actually developed as a pharmaceutical through the 1980s and 1990s.

Its main clinical use was diagnostic: a single bolus injection to see whether the pituitary could produce GH on demand, which helps separate a hypothalamic cause of GH deficiency from a pituitary one. That diagnostic use was the basis for FDA marketing authorisation under the brand name Geref.

Beyond diagnostics, the published clinical work on GHRH (1-29) sits mostly in older healthy adults, not in classically GH-deficient patients. A 1997 study in Metabolism by Vittone and colleagues gave single nightly subcutaneous injections of GHRH (1-29) — the sermorelin sequence — to healthy elderly men, testing whether stimulating the GHRH receptor could augment the age-related decline in GH/IGF-1. A longer-term 1997 study in the Journal of Clinical Endocrinology and Metabolism by Khorram, Laughlin and Yen gave a sermorelin analog ([Nle27]GHRH-(1-29)-NH2) to age-advanced men and women over a sustained dosing period and tracked endocrine and metabolic effects.

Read the population, not just the result. This evidence is in healthy older adults, not in classically GH-deficient patients and not in younger people. Whether any of it transfers to someone whose GH is just age-lowered but still in normal range hasn’t been studied at controlled-trial scale.

The regulatory inheritance

Sermorelin’s regulatory history is genuinely interesting. Geref (sermorelin acetate for injection) received two separate FDA marketing authorisations — NDA 019863, approved December 1990 for diagnostic evaluation of GH secretion, and NDA 020443, approved September 26, 1997 for treatment of pediatric idiopathic GH deficiency. That makes sermorelin the one peptide here that completed the full drug development and approval process — twice — for defined indications. Both approvals were withdrawn effective June 18, 2009 for commercial reasons, not safety: the active ingredient was no longer being manufactured and demand had declined. The FDA explicitly confirmed the withdrawal was not for safety or efficacy.

After withdrawal, sermorelin became available through compounding pharmacies in the US. Its prior approval gave it more standing than most compounded peptides, and anti-aging and endocrinology practices have used the compounded form for GH deficiency management.

Sermorelin isn’t on the PCAC July 23–24, 2026 agenda — and it doesn’t need to be. It runs under the pre-existing compounding framework that survived the Geref withdrawals, not the PCAC bulk substances process that applies to newer, less-evaluated compounds.

WADA’s 2026 Prohibited List S2 category — Growth Hormone Releasing Factors and their analogs — covers sermorelin. If you compete, treat it as prohibited, in and out of competition.

Where the data thins

This is the honest part, so read it twice.

Efficacy in GH-sufficient people is not established. The clinical evidence is in deficient patients. Whether sermorelin does anything meaningful in someone whose GH is age-related but within normal range hasn’t been rigorously studied.

The healthspan pitch from anti-aging medicine — that sermorelin-driven GH optimisation improves metabolism, body composition, and longevity in healthy older adults — isn’t well-supported by published RCT data in non-deficient populations. It’s a hypothesis wearing a clinical history that belongs to a different population.

Long-term effects of sustained GHRH analog use on pituitary function, IGF-1 levels, and downstream pathways, including IGF-1’s role in cell proliferation, haven’t been studied in the longevity context.

Where sermorelin lands

Sermorelin is the most clinically characterised peptide in the GH secretagogue class. It went through full drug development, got marketing authorisation, and left behind an evidence base newer compounds don’t have. That history gives it legitimacy pure research-stage compounds can’t claim.

The honest framing, if you’re tracking this: the clinical record is real but it’s in GH-deficient patients, the population most interested in it is healthy aging adults, and no published RCT has bridged that gap. The legitimacy is genuine. The evidence for the use people actually want isn’t there yet.